BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 1635087)

  • 1. l-folinic acid versus d,l-folinic acid in rescue of high-dose methotrexate therapy in children.
    Etienne MC; Thyss A; Bertrand Y; Touraine R; Rubie H; Robert A; Milano G
    J Natl Cancer Inst; 1992 Aug; 84(15):1190-5. PubMed ID: 1635087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [l-folinic acid versus racemic folinic acid in the treatment of leukemia in children with high dose of methotrexate].
    Etienne MC; Thyss A; Bertrand Y; Rubie H; Milano G
    Bull Cancer; 1993 Apr; 80(4):357-63. PubMed ID: 8173189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue.
    Wolfrom C; Hepp R; Hartmann R; Breithaupt H; Henze G
    Eur J Clin Pharmacol; 1990; 39(4):377-83. PubMed ID: 2076721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for CSF accumulation of 5-methyltetrahydrofolate during repeated courses of methotrexate plus folinic acid rescue.
    Thyss A; Milano G; Etienne MC; Paquis P; Roche JL; Grelier P; Schneider M
    Br J Cancer; 1989 Apr; 59(4):627-30. PubMed ID: 2785400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in intracellular folate metabolism during high-dose methotrexate and Leucovorin rescue therapy in children with acute lymphoblastic leukemia.
    Oosterom N; de Jonge R; Smith DEC; Pieters R; Tissing WJE; Fiocco M; van Zelst BD; van den Heuvel-Eibrink MM; Heil SG
    PLoS One; 2019; 14(9):e0221591. PubMed ID: 31527879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evaluation of red blood cell folate and methotrexate levels during protocol M in childhood acute lymphoblastic leukemia.
    Oosterom N; Fiocco M; Kloos RQH; van der Sluis IM; Pieters R; van Zelst BD; Smith DEC; van den Heuvel-Eibrink MM; de Jonge R; Heil SG
    BMC Cancer; 2020 Sep; 20(1):940. PubMed ID: 32998716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rescue after intermediate and high-dose methotrexate: background, rationale, and current practice.
    Borsi JD; Sagen E; Romslo I; Moe PJ
    Pediatr Hematol Oncol; 1990; 7(4):347-63. PubMed ID: 2268535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].
    Zhang H; He X; Li J; Wang Y; Wang C; Chen Y; Niu C; Gao P
    Zhonghua Er Ke Za Zhi; 2014 Oct; 52(10):770-6. PubMed ID: 25537545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving the safety of high-dose methotrexate for children with hematologic cancers in settings without access to MTX levels using extended hydration and additional leucovorin.
    Vaishnavi K; Bansal D; Trehan A; Jain R; Attri SV
    Pediatr Blood Cancer; 2018 Dec; 65(12):e27241. PubMed ID: 29768710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical factors for the reversal of methotrexate cytotoxicity by folinic acid.
    Bernard S; Etienne MC; Fischel JL; Formento P; Milano G
    Br J Cancer; 1991 Feb; 63(2):303-7. PubMed ID: 1997110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenging the clinical relevance of folinic acid over rescue after high dose methotrexate (HDMTX).
    Cohen IJ
    Med Hypotheses; 2013 Nov; 81(5):942-7. PubMed ID: 24035689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of low-risk gestational trophoblastic neoplasia comparing biweekly eight-day Methotrexate with folinic acid versus bolus-dose Actinomycin-D, among Brazilian women.
    Uberti EM; Fajardo Mdo C; da Cunha AG; Frota SS; Braga A; Ayub AC
    Rev Bras Ginecol Obstet; 2015 Jun; 37(6):258-65. PubMed ID: 26200823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substitution of l-leucovorin for d,l-leucovorin in the rescue from high-dose methotrexate treatment in patients with osteosarcoma.
    Jaffe N; Jorgensen K; Robertson R; George M; Letvak L; Barrett G
    Anticancer Drugs; 1993 Oct; 4(5):559-64. PubMed ID: 8292813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced citrovorum factor rescue for high-dose methotrexate therapy in childhood malignancies.
    Sasaki K; Tanaka J; Murakami T; Matuoka H; Fujimoto T; Taguchi H
    Cancer Drug Deliv; 1985; 2(1):77-86. PubMed ID: 3876873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced dose folinic acid rescue after rapid high-dose methotrexate clearance is not associated with increased toxicity in a pediatric cohort.
    Niinimäki R; Aarnivala H; Banerjee J; Pokka T; Vepsäläinen K; Harila-Saari A
    Support Care Cancer; 2022 Jan; 30(1):127-133. PubMed ID: 34235555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How much is too much? Folinic acid rescue dose in children with acute lymphoblastic leukaemia.
    Borsi JD; Wesenberg F; Stokland T; Moe PJ
    Eur J Cancer; 1991; 27(8):1006-9. PubMed ID: 1832883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of reduced folates with methotrexate or 5-fluorouracil. Comparison between 5-formyltetrahydrofolate (folinic acid) and 5-methyltetrahydrofolate in vitro activities.
    Etienne MC; Fischel JL; Formento P; Schneider M; Guillot T; Bardon M; Milano G
    Biochem Pharmacol; 1993 Nov; 46(10):1767-74. PubMed ID: 8250962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian population model of methotrexate to guide dosage adjustments for folate rescue in patients with breast cancer.
    Monjanel-Mouterde S; Lejeune C; Ciccolini J; Merite N; Hadjaj D; Bonnier P; Piana P; Durand A
    J Clin Pharm Ther; 2002 Jun; 27(3):189-95. PubMed ID: 12081632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rescuing effect of folates on methotrexate cytotoxicity in human trophoblast cells.
    Ravaei A; Rubini M
    Clin Exp Rheumatol; 2022 Jul; 40(7):1403-1410. PubMed ID: 34665710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.
    Widemann BC; Balis FM; Kim A; Boron M; Jayaprakash N; Shalabi A; O'Brien M; Eby M; Cole DE; Murphy RF; Fox E; Ivy P; Adamson PC
    J Clin Oncol; 2010 Sep; 28(25):3979-86. PubMed ID: 20679598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.